BNTC
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
Benitec Biopharma Inc. (BNTC) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (C+); its weakest is Momentum (D+). The rating has held at C for 6 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | C+ (2.5) | D+ (1.8) | C+ (2.7) | D+ (1.7) | C+ (2.6) | C (2.3) |
| 2026-11-10 | C+ (2.5) | C- (1.9) | C+ (2.7) | C- (1.9) | C+ (2.6) | C (2.3) |
| 2026-11-03 | C+ (2.5) | D+ (1.8) | C+ (2.7) | D+ (1.7) | C+ (2.7) | C (2.3) |
| 2026-10-27 | C+ (2.5) | C- (1.9) | C+ (2.8) | D+ (1.7) | C+ (2.6) | C (2.3) |
| 2026-10-20 | C+ (2.5) | D+ (1.8) | C+ (2.8) | D+ (1.8) | C+ (2.6) | C (2.3) |